POSTERS ASCO 2024

Terapias en desarrollo

Agentes molecularmente dirigidos y biología tumoral

177Lu-edotreotide versus everolimus in patients with advanced neuroendocrine tumors of lung or thymic origin: The phase 3 randomized LEVEL, GETNE-T2217 trial.

177Lu-edotreotide versus everolimus in patients with advanced neuroendocrine tumors of lung or thymic origin: The phase 3 randomized LEVEL, GETNE-T2217 trial.

Abstract: TPS3177 Poster Bd #: 313b

Poster

Descargar

Autor
Alejandro García-Álvarez, MD

Medical Oncology Department. Vall Hebron University Hospital, Vall Hebron Institute of Oncology (VHIO)

Compartir:

Una iniciativa científica de:

eco clover

Con el patrocinio de:

REGENERON